Actinium Pharmaceuticals, Inc.
ATNM · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -128.9% | – | – | – |
| R&D Expenses | $4 | $5 | $7 | $5 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $3 | $9 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $6 | $7 | $16 | $7 |
| Operating Income | -$6 | -$8 | -$17 | -$8 |
| % Margin | -6,324.4% | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $1 | $1 |
| Pre-Tax Income | -$5 | -$7 | -$16 | -$7 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$7 | -$16 | -$7 |
| % Margin | -5,701.1% | – | – | – |
| EPS | -0.16 | -0.22 | -0.51 | -0.21 |
| % Growth | 27.3% | 56.9% | -142.9% | – |
| EPS Diluted | -0.16 | -0.22 | -0.51 | -0.21 |
| Weighted Avg Shares Out | 31 | 31 | 31 | 31 |
| Weighted Avg Shares Out Dil | 31 | 31 | 31 | 31 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$7 | -$16 | -$6 |
| % Margin | -5,472.2% | – | – | – |